|
1
|
Wilson RR: Radiological use of fast
protons. Radiology. 47:487–491. 1946. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lawrence JH, Tobias CA, Born JL, McCombs
RK, Roberts JE, Anger HO, Low-Beer BV and Huggins CB: Pituitary
irradiation with high-energy proton beams: A preliminary report.
Cancer Res. 18:121–134. 1958.PubMed/NCBI
|
|
3
|
Bragg WH and Kleeman R: XXXIX. On the α
particles of radium, and their loss of range in passing through
various atoms and molecules. Philos Mag. 10:318–340. 1905.
View Article : Google Scholar
|
|
4
|
Jäkel O, Smith AR and Orton CG: The more
important heavy charged particle radiotherapy of the future is more
likely to be with heavy ions rather than protons. Med Phys.
40:0906012013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paganetti H, Niemierko A, Ancukiewicz M,
Gerweck LE, Goitein M, Loeffler JS and Suit HD: Relative biological
effectiveness (RBE) values for proton beam therapy. Int J Radiat
Oncol Biol Phys. 53:407–421. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paganetti H, Niemierko A, Ancukiewicz M,
Gerweck LE, Goitein M, Loeffler JS and Suit HD: Relative biological
effectiveness (RBE) values for proton beam therapy. Int J Radiat
Oncol Biol Phys. 53:407–421. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van de Water TA, Lomax AJ, Bijl HP, De
Jong ME, Schilstra C, Hug EB and Langendijk JA: Potential benefits
of scanned intensity-modulated proton therapy versus advanced
photon therapy with regard to sparing of the salivary glands in
oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 79:1216–1224.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Slater JD, Yonemoto LT, Mantik DW, Bush
DA, Preston W, Grove RI, Miller DW and Slater JM: Proton radiation
for treatment of cancer of the oropharynx: Early experience at Loma
Linda university medical center using a concomitant boost
technique. Int J Radiat Oncol Biol Phys. 62:494–500. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fitzek MM, Thornton AF, Varvares M,
Ancukiewicz M, Mcintyre J, Adams J, Rosenthal S, Joseph M and
Amrein P: Neuroendocrine tumors of the sinonasal tract. Results of
a prospective study incorporating chemotherapy, surgery, and
combined proton-photon radiotherapy. Cancer. 94:2623–2634. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Truong MT, Kamat UR, Liebsch NJ, Curry WT,
Lin DT, Barker FG II, Loeffler JS and Chan AW: Proton radiation
therapy for primary sphenoid sinus malignancies: Treatment outcome
and prognostic factors. Head Neck. 31:1297–1308. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fuji H, Yoshikawa S, Kasami M, Murayama S,
Onitsuka T, Kashiwagi H and Kiyohara Y: High-dose proton beam
therapy for sinonasal mucosal malignant melanoma. Radiat Oncol.
9:1622014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moriarty JP, Borah BJ, Foote RL, Pulido JS
and Shah ND: Cost-effectiveness of proton beam therapy for
intraocular melanoma. PLoS One. 10:e01278142015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ahmed KA, Demetriou SK, McDonald M and
Johnstone PA: Clinical benefits of proton beam therapy for tumors
of the skull base. Cancer Control. 23:213–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sakurai H, Ishikawa H and Okumura T:
Proton beam therapy in Japan: Current and future status. Jpn J Clin
Oncol. 46:885–892. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Berman AT, James SS and Rengan R: Proton
beam therapy for non-small cell lung cancer: Current clinical
evidence and future directions. Cancers (Basel). 7:1178–1190. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu CT, Motegi A, Motegi K, Hotta K, Kohno
R, Tachibana H, Kumagai M, Nakamura N, Hojo H, Niho S, et al:
Dosimetric comparison between proton beam therapy and photon
radiation therapy for locally advanced non-small cell lung cancer.
Jpn J Clin Oncol. Aug 10–2016.(Epub ahead of print). View Article : Google Scholar
|
|
17
|
Bradley JD, Bae K, Graham MV, Byhardt R,
Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E and Choy H:
Primary analysis of the phase II component of a phase I/II dose
intensification study using three-dimensional conformal radiation
therapy and concurrent chemotherapy for patients with inoperable
non-small-cell lung cancer: RTOG 0117. J Clin Oncol. 28:2475–2480.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iwata H, Demizu Y, Fujii O, Terashima K,
Mima M, Niwa Y, Hashimoto N, Akagi T, Sasaki R, Hishikawa Y, et al:
Long-term outcome of proton therapy and carbon-ion therapy for
large (T2a-T2bN0M0) non-small-cell lung cancer. J Thorac Oncol.
8:726–735. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dunlap NE, Larner JM, Read PW, Kozower BD,
Lau CL, Sheng K and Jones DR: Size matters: A comparison of T1 and
T2 peripheral non-small-cell lung cancers treated with stereotactic
body radiation therapy (SBRT. J Thorac Cardiovasc Surg.
140:583–589. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanemoto A, Okumura T, Ishikawa H,
Mizumoto M, Oshiro Y, Kurishima K, Homma S, Hashimoto T, Ohkawa A,
Numajiri H, et al: Outcomes and prognostic factors for recurrence
after high-dose proton beam therapy for centrally and peripherally
located stage I non-small-cell lung cancer. Clin Lung Cancer.
15:e7–e12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Socinski MA, Blackstock AW, Bogart JA,
Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper
A, et al: Randomized phase II trial of induction chemotherapy
followed by concurrent chemotherapy and dose-escalated thoracic
conformal radiotherapy (74 Gy) in stage III non-small-cell lung
cancer. J Clin Oncol. 26:2457–2463. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koto M, Takai Y, Ogawa Y, Matsushita H,
Takeda K, Takahashi C, Britton KR, Jingu K, Takai K, Mitsuya M, et
al: A phase II study on stereotactic body radiotherapy for stage I
non-small cell lung cancer. Radiother Oncol. 85:429–434. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rosenman JG, Halle JS, Socinski MA,
Deschesne K, Moor DT, Johnson H, Fraser R and Morris DE: High-dose
conformal radiotherapy for treatment of stage IIIA/IIIB
non-small-cell lung cancer: Technical issues and results of a phase
I/II trial. Int J Radiat Oncol Biol Phys. 54:348–356. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schild SE, Rule WG, Ashman JB, Vora SA,
Keole S, Anand A, Liu W and Bues M: Proton beam therapy for locally
advanced lung cancer: A review. World J Clin Oncol. 5:568–575.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang JY, Komaki R, Lu C, Wen HY, Allen
PK, Tsao A, Gillin M, Mohan R and Cox JD: Phase 2 study of
high-dose proton therapy with concurrent chemotherapy for
unresectable stage III nonsmall celllung cancer. Cancer.
117:4707–4713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cox JD: Are the results of RTOG 0617
mysterious? Int J Radiat Oncol Biol Phys. 82:1042–1044. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oshiro Y, Okumura T, Kurishima K, Homma S,
Mizumoto M, Ishikawa H, Onizuka M, Sakai M, Goto Y, Hizawa N, et
al: High-dose concurrent chemo-proton therapy for Stage III NSCLC:
Preliminary results of a Phase II study. J Radiat Res. 55:959–965.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bradley JD, Paulus R, Komaki R, Masters G,
Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A,
et al: Standard-dose versus high-dose conformal radiotherapy with
concurrent and consolidation carboplatin plus paclitaxel with or
without cetuximab for patients with stage IIIA or IIIB
non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two
factorial phase 3 study. Lancet Oncol. 16:187–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ohno T, Oshiro Y, Mizumoto M, Numajiri H,
Ishikawa H, Okumura T, Terunuma T, Sakae T and Sakurai H:
Comparison of dose-volume histograms between proton beam and X-ray
conformal radiotherapy for locally advanced non-small-cell lung
cancer. J Radiat Res. 56:128–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takada A, Nakamura T, Takayama K, Makita
C, Suzuki M, Azami Y, Kato T, Tsukiyama I, Hareyama M, Kikuchi Y,
et al: Preliminary treatment results of proton beam therapy with
chemoradiotherapy for stage I–III esophageal cancer. Cancer Med.
5:506–515. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kato K, Muro K, Minashi K, Ohtsu A,
Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y and Fukuda H;
Gastrointestinal Oncology Study Group of the Japan Clinical
Oncology Group (JCOG), : Phase II study of chemoradiotherapy with
5-fluorouracil and cisplatin for Stage II–III esophageal squamous
cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol
Phys. 81:684–690. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ishikura S, Nihei K, Ohtsu A, Boku N,
Hironaka S, Mera K, Muto M, Ogino T and Yoshida S: Long-term
toxicity after definitive chemoradiotherapy for squamous cell
carcinoma of the thoracic esophagus. J Clin Oncol. 21:2697–2702.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shirai K, Tamaki Y, Kitamoto Y, Murata K,
Satoh Y, Higuchi K, Nonaka T, Ishikawa H, Katoh H, Takahashi T and
Nakano T: Dose-volume histogram parameters and clinical factors
associated with pleural effusion after chemoradiotherapy in
esophageal cancer patients. Int J Radiat Oncol Biol Phys.
80:1002–1007. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Morota M, Gomi K, Kozuka T, Chin K,
Matsuura M, Oguchi M, Ito H and Yamashita T: Late toxicity after
definitive concurrent chemoradiotherapy for thoracic esophageal
carcinoma. Int J Radiat Oncol Biol Phys. 75:122–128. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okonogi N, Hashimoto T, Ishida M, Ohno T,
Terunuma T, Okumura T, Sakae T and Sakurai H: Designed-seamless
irradiation technique for extended whole mediastinal proton-beam
irradiation foresophageal cancer. Radiat Oncol. 7:1732012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ishikawa H, Hashimoto T, Moriwaki T, Hyodo
I, Hisakura K, Terashima H, Ohkohchi N, Ohno T, Makishima H,
Mizumoto M, et al: Proton beam therapy combined with concurrent
chemotherapy for esophageal cancer. Anticancer Res. 35:1757–1762.
2015.PubMed/NCBI
|
|
37
|
Koyama S and Tsujii H: Proton beam therapy
with high-dose irradiation for superficial and advanced esophageal
carcinomas. Clin Cancer Res. 9:3571–3577. 2003.PubMed/NCBI
|
|
38
|
Mizumoto M, Sugahara S, Nakayama H, Hashii
H, Nakahara A, Terashima H, Okumura T, Tsuboi K, Tokuuye K and
Sakurai H: Clinical results of proton-beam therapy for
locoregionally advanced esophageal cancer. Strahlenther Onkol.
186:482–488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sugahara S, Tokuuye K, Okumura T, Nakahara
A, Saida Y, Kagei K, Ohara K, Hata M, Igaki H and Akine Y: Clinical
results of proton beam therapy for cancer of the esophagus. Int J
Radiat Oncol Biol Phys. 61:76–84. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Makishima H, Ishikawa H, Terunuma T,
Hashimoto T, Yamanashi K, Sekiguchi T, Mizumoto M, Okumura T, Sakae
T and Sakurai H: Comparison of adverse effects of proton and X-ray
chemoradiotherapy for esophageal cancer using an adaptive
dose-volume histogram analysis. J Radiat Res. 56:568–576. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin SH, Hallemeier CL and Chuong M: Proton
beam therapy for the treatment of esophageal cancer. Chin Clin
Oncol. 5:532016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ono T, Nakamura T, Azami Y, Yamaguchi H,
Hayashi Y, Suzuki M, Hatayama Y, Tsukiyama I, Hareyama M, Kikuchi Y
and Nemoto K: Clinical results of proton beam therapy for twenty
older patients with esophageal cancer. Radiol Oncol. 49:371–378.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chuong MD, Hallemeier CL, Jabbour SK, Yu
J, Badiyan S, Merrell KW, Mishra MV, Li H, Verma V and Lin SH:
Improving outcomes for esophageal cancer using proton beam therapy.
Int J Radiat Oncol Biol Phys. 95:488–497. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Reiazi R, Norozi A and Etedadialiabadi M:
A Literature survey on cost-Effectiveness of proton beam therapy in
the management of breast cancer patients. Iran J Cancer Prev.
8:e43732015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Johansson J, Isacsson U, Lindman H,
Montelius A and Glimelius B: Node-positive left-sided breast cancer
patients after breast-conserving surgery: Potential outcomes of
radiotherapy modalities and techniques. Radiother Oncol. 65:89–98.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kozak KR, Smith BL, Adams J, Kornmehl E,
Katz A, Gadd M, Specht M, Hughes K, Gioioso V, Lu HM, et al:
Accelerated partial-breast irradiation using proton beams: Initial
clinical experience. Int J Radiat Oncol Biol Phys. 66:691–698.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kozak KR, Katz A, Adams J, Crowley EM,
Nyamwanda JA, Feng JK, Doppke KP, Delaney TF and Taghian AG:
Dosimetric comparison of proton and photon three-dimensional,
conformal, external beam accelerated partial breast irradiation
techniques. Int J Radiat Oncol Biol Phys. 65:1572–1578. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lomax AJ, Cella L, Weber D, Kurtz JM and
Miralbell R: Potential role of intensity-modulated photons and
protons in the treatment of the breast and regional nodes. Int J
Radiat Oncol Biol Phys. 55:785–792. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bush DA, Slater JD, Garberoglio C, Do S,
Lum S and Slater JM: Partial breast irradiation delivered with
proton beam: Results of a phase II trial. Clin Breast Cancer.
11:241–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Weber DC, Ares C, Lomax AJ and Kurtz JM:
Radiation therapy planning with photons and protons for early and
advanced breast cancer: An overview. Radiat Oncol. 1:222006.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lundkvist J, Ekman M, Ericsson SR,
Isacsson U, Jönsson B and Glimelius B: Economic evaluation of
proton radiation therapy in the treatment of breast cancer.
Radiother Oncol. 75:179–185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Clarke M, Collins R, Darby S, Davies C,
Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, et al:
Effects of radiotherapy and of differences in the extent of surgery
for early breast cancer on local recurrence and 15-year survival:
An overview of the randomised trials. Lancet. 366:2087–2106. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bush DA, Slater JD, Garberoglio C, Yuh G,
Hocko JM and Slater JM: A technique of partial breast irradiation
utilizing proton beam radiotherapy: comparison with conformal x-ray
therapy. Cancer J. 13:114–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Taghian AG, Kozak KR, Katz A, Adams J, Lu
HM, Powell SN and DeLaney TF: Accelerated partial breast
irradiation using proton beams: initial dosimetric experience. Int
J Radiat Oncol Biol Phys. 65:1404–1410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mahal BA, Chen YW, Efstathiou JA,
Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio
PF III and Nguyen PL: National trends and determinants of proton
therapy use for prostate cancer: A national cancer data base study.
Cancer. 122:1505–1512. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hoppe BS, Michalski JM, Mendenhall NP,
Morris CG, Henderson RH, Nichols RC, Mendenhall WM, Williams CR,
Regan MM, Chipman JJ, et al: Comparative effectiveness study of
patient-reported outcomes after proton therapy or
intensitymodulated radiotherapy for prostate cancer. Cancer.
120:1076–1082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sheets NC, Goldin GH, Meyer AM, Wu Y,
Chang Y, Stürmer T, Holmes JA, Reeve BB, Godley PA, Carpenter WR
and Chen RC: Intensity-modulated radiation therapy, proton therapy,
or conformal radiation therapy and morbidity and disease control in
localized prostate cancer. JAMA. 307:1611–1620. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hospital MG, Pennsylvania Uo; (NCI) NCI, ;
et al: Proton therapy vs. IMRT for low or intermediate risk
prostate cancer (PARTIQoL). https://clinicaltrials.gov/ct2/show/NCT01617161June
12–2012
|
|
59
|
Zaorsky NG, Harrison AS, Trabulsi EJ,
Gomella LG, Showalter TN, Hurwitz MD, Dicker AP and Den RB:
Evolution of advanced technologies in prostate cancer radiotherapy.
Nat Rev Urol. 10:565–579. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Pugh TJ and Lee AK: Proton beam therapy
for the treatment of prostate cancer. Cancer J. 20:415–420. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Johnstone PA, McMullen KP, Buchsbaum JC,
Douglas JG and Helft P: Pediatric CSI: Are protons the only ethical
approach? Int J Radiat Oncol Biol Phys. 87:228–230. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sethi RV, Shih HA, Yeap BY, Mouw KW,
Petersen R, Kim DY, Munzenrider JE, Grabowski E, Rodriguez-Galindo
C, Yock TI, et al: Second nonocular tumors among survivors of
retinoblastoma treated with contemporary photon and proton
radiotherapy. Cancer. 120:126–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Taddei PJ, Mirkovic D, Fontenot JD,
Giebeler A, Zheng Y, Kornguth D, Mohan R and Newhauser WD: Stray
radiation dose and second cancer risk for a pediatric patient
receiving craniospinal irradiation with proton beams. Phys Med
Biol. 54:2259–2275. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Merchant TE, Kiehna EN, Li C, Shukla H,
Sengupta S, Xiong X, Gajjar A and Mulhern RK: Modeling radiation
dosimetry to predict cognitive outcomes in pediatric patients with
CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol
Biol Phys. 65:210–221. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Miralbell R, Lomax A, Cella L and
Schneider U: Potential reduction of the incidence of
radiation-induced second cancers by using proton beams in the
treatment of pediatric tumors. Int J Radiat Oncol Biol Phys.
54:824–829. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Athar BS and Paganetti H: Comparison of
second cancer risk due to out-of-field doses from 6-MV IMRT and
proton therapy based on 6 pediatric patient treatment plans.
Radiother Oncol. 98:87–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lee CT, Bilton SD, Famiglietti RM, Riley
BA, Mahajan A, Chang EL, Maor MH, Woo SY, Cox JD and Smith AR:
Treatment planning with protons for pediatric retinoblastoma,
medulloblastoma, and pelvic sarcoma: How do protons compare with
other conformal techniques? Int J Radiat Oncol Biol Phys.
63:362–372. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yock T, Schneider R, Friedmann A, Adams J,
Fullerton B and Tarbell N: Proton radiotherapy for orbital
rhabdomyosarcoma: Clinical outcome and a dosimetric comparison with
photons. Int J Radiat Oncol Biol Phys. 63:1161–1168. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mu X, Björk-Eriksson T, Nill S, Oelfke U,
Johansson KA, Gagliardi G, Gagliardi G, Johansson L, Karlsson M and
Zackrisson DB: Does electron and proton therapy reduce the risk of
radiation induced cancer after spinal irradiation for childhood
medulloblastoma? A comparative treatment planning study. Acta
Oncol. 44:554–562. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Heidenreich PA, Schnittger I, Strauss HW,
Vagelos RH, Lee BK, Mariscal CS, Tate DJ, Horning SJ, Hoppe RT and
Hancock SL: Screening for coronary artery disease after mediastinal
irradiation for Hodgkin's disease. J Clin Oncol. 25:43–49. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Hull MC, Morris CG, Pepine CJ and
Mendenhall NP: Valvular dysfunction and carotid, subclavian, and
coronary artery disease in survivors of hodgkin lymphoma treated
with radiation therapy. JAMA. 290:2831–2837. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Foote RL, Stafford SL, Petersen IA, Pulido
JS, Clarke MJ, Schild SE, Garces YI, Olivier KR, Miller RC, Haddock
MG, et al: The clinical case for proton beam therapy. Radiat Oncol.
7:1742012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sejpal S, Komaki R, Tsao A, Chang JY, Liao
Z, Wei X, Allen PK, Lu C, Gillin M and Cox JD: Early findings on
toxicity of proton beam therapy with concurrent chemotherapy for
nonsmall cell lung cancer. Cancer. 117:3004–3013. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Plastaras JP, Berman AT and Freedman GM:
Special cases for proton beam radiotherapy: Re-irradiation,
lymphoma, and breast cancer. Semin Oncol. 41:807–819. 2014.
View Article : Google Scholar : PubMed/NCBI
|
